key: cord-0768460-q2z4hlim
authors: Honarmand, Amir Reza; Mackey, Justin; Hayeri, Reza
title: Shoulder injury related to vaccine administration (SIRVA) following mRNA COVID-19 vaccination: Report of 2 cases of subacromial-subdeltoid bursitis
date: 2021-10-01
journal: Radiol Case Rep
DOI: 10.1016/j.radcr.2021.08.019
sha: 727a705ca2601aa5216d8e447873a3f749fa4e0f
doc_id: 768460
cord_uid: q2z4hlim

Shoulder pain has been reported as a common side-effect after COVID-19 vaccination particularly after administration of mRNA vaccines. Although it is usually mild and self-limiting, occasionally it can become more extensive causing severe pain and marked limited range of motion. Shoulder injury related to vaccine administration has been reported following injection of other routine vaccines. In this case report, we describe 2 cases of shoulder injury related to vaccine administration due to subacromial-subdeltoid bursitis after administration of mRNA COVID-19 vaccines.

As the widespread use of COVID-19 vaccination is ongoing worldwide, radiologists have become more aware of its related imaging findings. Incidental axillary lymphadenopathy has been among the initially recognized and widely reported post vaccination findings in different imaging modalities [1] [2] [3] [4] . On the other hand, post-vaccination arm/shoulder pain, particularly at the site of injection, has been reported as one of the most common vaccine related side effects though usually self-limiting and resolving within a few days with or ✩ Competing interests: Authors have no conflict of interest, grants or other funding resources to disclose. * Corresponding author. A.R Honarmand.

E-mail address: ahonarmand@mgh.harvard.edu (A.R. Honarmand). without conservative treatment for which imaging examination is rarely needed. Shoulder injury related to vaccine administration (SIRVA) is a well-known entity described previously and before the COVID-19 era with other types of vaccinations, particularly influenza vaccine [5] [6] [7] . SIRVA includes a variety of conditions such as adhesive capsulitis, tendinitis, and subacromial-subdeltoid bursitis. A recent case report described a case of SIRVA, specifically subacromial-subdeltoid bursitis, after administration of Oxford-AstraZeneca vaccine (Serum Institute of India) [8] . In this paper, we report 2 cases of SIRVA, namely subacromial-subdeltoid bursitis, after administration of mRNA COVID-19 vaccines. 

A 38-year-old male right-handed healthcare worker with no significant past medical history presented with non-traumatic severe left shoulder pain (numerical pain rating scale of 10/10). The symptoms developed 2 weeks after receiving the second dose of Pfizer-BioNTech COVID19 vaccine (BNT162b2) leading to severe limited range of motion. The patient did not report any significant vaccine related symptoms with the first dose of vaccine except for moderate arm pain around the injection site. There was no report of deep or high injection site at the time of vaccine administration. Subsequently, ultrasound of the left shoulder was performed in which subacromialsubdeltoid bursitis was detected ( Fig. 2 ) . The symptoms almost completely resolved by conservative management in less than a week.

Data available from United States clinical trials suggest that mRNA COVID-19 vaccines, Pfizer-BioNTech and Moderna, can be highly immunogenic which can affect their reactogenicity and subsequently their side-effect profiles. Given the short time frame since the introduction of mRNA COVID-19 vaccines, the exact pathophysiology of their side-effects has not been fully understood; however, it has been postulated that it may be related to lipid nanoparticle and formulation components or the sequence selection for the vaccine RNA [9] . Reactogenicity of vaccines has been previously contributed to adjuvants routinely utilized to enhance immunogenicity of the vaccines via increasing the antigen-specific response.

On the other hand, adjuvants can simultaneously increase the probability of autoimmune reactions which has been defined and described as autoimmune/inflammatory syndrome induced by adjuvants (ASIA) or Shoenfeld's syndrome. Specifically, ASIA is characterized by the appearance of myalgia, myositis, muscle weakness, arthralgia, arthritis, chronic fatigue, sleep disturbances, cognitive impairment/memory loss, and possible emergence of a demyelinating autoimmune disease caused by systemic exposure after administration of vaccines and adjuvants [10] . Nevertheless, majority of the population receiving mRNA COVID-19 vaccines demonstrate at least 1 or more local or systemic symptoms [11] . This may have some impact on radiological findings of recently vaccinated population being referred to imaging centers. One of the most common side effects of the COVID-19 vaccines has been reported as pain, redness, and swelling in the arm where the vaccine is administered followed by other common systemic side effects such as headache, fever, tiredness, myalgia, fatigue [11] . Arm pain due to vaccine injection usually resolves within a few days with or without conservative treatment. However, in some cases, the severity of the arm pain is out of proportion and may extend to other surrounding structures resulting in SIRVA. As mentioned before, SIRVA has been reported after administration of other routine vaccines and can include variety of conditions such as adhesive capsulitis, tendinitis, and subacromial-subdeltoid bursitis. When clinical symptoms become out of proportion that they cannot be contributed to injection induced muscle pain only, imaging can help to investigate the presence of SIRVA.

Both patients who experienced subacromial-subdeltoid bursitis in our case report routinely received the influenza vaccine annually without development of SIRVA. Although clinical symptoms were similar, the time frame of symptom development was different between our reported cases suggesting different pathophysiologies for development of subacromialsubdeltoid bursitis. The patient in our first case reported a high injection site and acute pain shortly after administration of the vaccine. This favored probable direct and local effect of the vaccine likely due to high level or deep intrabursal injection as suggested on the MR image ( Fig. 1 A) . This was similar to the reported case of SIRVA due to Oxford-AstraZeneca vaccine in whom the symptoms of subacromial-subdeltoid bursitis developed immediately after administration of the first dose followed by persistent pain and worsening of range of motion [8] . Similarly, Atanasoff et al described 13 cases of SIRVA which developed rapidly (immediate to 4 days) after receiving different types of vaccines. They proposed unintentional injection of the antigenic material into synovial tissue and subsequent immune-mediated inflammatory reaction as the possible underlying mechanism [12] . Intrabursal injection can be contributed to either deep or high-level of injection and as such can be avoided by proper injection techniques [8] . Anatomical variation can also contribute to intrabursal injection. Bodor et al previously described 2 SIRVA cases in whom the bursa was extended beyond the lateral border of the acromion locating just below the skin surface where a vaccine needle is easily accessible [13] .

Our second case, however, had a subacute course with subacromial-subdeltoid bursitis that developed 2 weeks after administration of the vaccine. In the absence of any prior shoulder condition or triggering injury, developing subacromial-subdeltoid bursitis was clinically contributed to the vaccination as well. However, the 2-week time frame between injection and developing bursitis favored a pathophysiology other than intrabursal injection. One possible mechanism could be delayed inflammatory response to injection or ASIA. Alternatively, although rare, cases of myositis leading to bursitis were reported in literature [14] .

To our knowledge our cases are the first reported cases of imaging and clinically proven SIRVA due to mRNA COVID-19 vaccines. Given the widespread COVID-19 vaccination clinicians and radiologists should be familiar with potential musculoskeletal side effects of these vaccines.

Written informed consents for publication of the cases were obtained from the patients and will be available upon request.

COVID-19) vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women

Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of Coronavirus Disease (COVID-19) vaccination

Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients. Radiology 2021:210275 Epub ahead of print

Unilateral axillary adenopathy in the setting of COVID-19 vaccine

Epub ahead of print

Influenza vaccine-related subacromial/subdeltoid bursitis: a case report

Post-influenza vaccine subdeltoid bursitis

Subdeltoid/subacromial bursitis associated with influenza vaccination

Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA)

First month of COVID-19 vaccine safety monitoring -United States

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects

Safety and immunogenicity of two RNA-based covid-19 vaccine candidates

Shoulder injury related to vaccine administration (SIRVA)

Vaccination-related shoulder dysfunction

Subscapular bursitis as a rare manifestation of dermatomyositis: a case report